Recruiting

Testing a radioactive treatment before prostate cancer surgery

Plain-English translation of NCT06798558 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called Lu-177-PSMA-617 (Pluvicto) given before surgery in men with high-risk prostate cancer. The medication is radioactive and targets cancer cells in the prostate. Researchers want to see if giving this treatment before surgery can help reduce the cancer and improve long-term outcomes.

High-risk prostate cancer is aggressive and has a higher chance of spreading. This medication has shown promise in treating advanced prostate cancer, but doctors don't yet know if giving it before surgery—rather than after—can help patients with early-stage disease do better.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with adenocarcinoma of the prostate with a Gleason Score of 8 or higher
your prostate shows high expression of PSMA on a special PET scan (68Ga-PSMA-11)
you are healthy enough to undergo prostate removal surgery and have a life expectancy of at least 10 years
you are willing and able to attend all follow-up visits for approximately 2 years after treatment

You likely don't qualify if…

you have previously received treatment for prostate cancer
you have received other radioactive cancer treatments within the past 6 months
you have cancer that has spread to sites outside the prostate on imaging scans
you are unable or unwilling to use contraception or avoid fathering children during treatment and for 14 weeks after

What participation looks like

You would receive two injections of the radioactive medication spaced 6 weeks apart. About 6 weeks after your second dose, you would have prostate removal surgery with removal of nearby lymph nodes. After surgery, you would return for safety check-ups at multiple time points over the first 3 months, then every 3 months for about 2 years to make sure you're doing well and to monitor for any side effects.

AI-generated summary from trial data · Jul 12, 2026 · Not medical advice

Trial locations(3 sites)

United States

MedStar Washington Hospital Center, Washington D.C., District of Columbia

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C., District of Columbia

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey